beyond glp-1 Obesity care isn't one-drug-fits-all. ​ Obesity management is evolving medications. ​ This session explores personalized approaches that improve outcomes across diverse patient populations. ​ Learn how non-GLP-1 therapies can support GLP-1-based therapies for diabetes, obesity

Maybe you hit your goal weight and decided you were done

It has widespread anti-inflammatory effects, which is one of the hallmarks of aging

Overall, more research is needed to fully understand ALCARs influence on cardiovascular health

According to the International Society of Aesthetic Plastic Surgery (ISAPS), nearly 38 million aesthetic procedures were performed globally in 2024, representing a 42.5% increase compared with 2020, highlighting the rising acceptance of cosmetic and wellness treatments

Cagrilintides longer measured half-life (roughly 78 days versus about 5 days for tirzepatide) is a pharmacokinetic fact from its own study not evidence of a better outcome

Drug Targets 13 , 256263 (2013)